SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$84.72
+6.03%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.78
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.36
- EPS estimate
- -$0.76
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +9.3%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $121
- PT range
- $110 – $130
- Analysts
- 8
7 Buy1 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.76 | -$0.36 | Beat 52.56% | — |
| May 5, 2026 | -$0.66 | -$0.74 | Miss -12.12% | — |
| Feb 19, 2026 | -$0.66 | -$0.70 | Miss -6.06% | $90.5M |
| May 8, 2025 | -$0.76 | -$0.74 | Beat 2.63% | — |
| Feb 27, 2025 | -$0.89 | -$0.81 | Beat 8.99% | — |
| Nov 7, 2024 | -$0.80 | -$1.36 | Miss -70.00% | — |
| May 9, 2024 | -$0.90 | -$1.20 | Miss -33.33% | — |
| Feb 29, 2024 | -$0.48 | -$2.28 | Miss -375.00% | $1.0M |
| Nov 9, 2023 | -$0.84 | -$9.34 | Miss -1011.90% | — |
| Aug 11, 2023 | -$4.50 | -$1.66 | Beat 63.11% | $688.0K |
| Mar 31, 2021 | — | -$6.94 | — | — |
| Sep 30, 2020 | — | -$7.24 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026